“Ozone depletion is a well-known phenomenon and, thanks to the success of the Montreal Protocol, is widely perceived as a problem solved,” says University of East Anglia’s David Oram. But an international team of researchers, led by Oram, has now found an unexpected, growing danger to the ozone layer from substances not regulated by the treaty. The study is published today in Atmospheric Chemistry and Physics, a journal of the European Geosciences Union.
articles
Is Climate Change Affecting Northern California's Devastating Fires?
On Monday I woke to the terrifying smell of smoke. From my home south of San Francisco, I could see the entire Bay Area covered in a thick layer, obscuring the sun.
Researchers explore ways to remove antibiotics polluting lakes and rivers
Pharmaceuticals, including antibiotics, are an increasingly common pollutant in water systems, said Catherine Hui Niu, associate professor in the Department of Chemical and Biological Engineering at the University of Saskatchewan.
Beyond Biodiversity: A New Way of Looking at How Species Interconnect
In 1966, an ecologist at the University of Washington named Robert Paine removed all the ochre starfish from a short stretch of Pacific shoreline on Washington’s Olympic Peninsula. The absence of the predator had a dramatic effect on its ecosystem. In less than a year, a diverse tidal environment collapsed into a monoculture of mussels because the starfish was no longer around to eat them.
Lakehead University and IISD Experimental Lakes Area team up to safeguard Canada's fresh water
Officials from Lakehead University and the International Institute for Sustainable Development Experimental Lakes Area (IISD-ELA) have signed a five-year memorandum of understanding to foster collaboration between the two organizations.
New Drug Hope for Patients with Rare Bone Cancer
Patients with a rare bone cancer of the skull and spine – chordoma – could be helped by existing drugs, suggest scientists from the Wellcome Trust Sanger Institute, University College London Cancer Institute and the Royal National Orthopaedic Hospital NHS Trust. In the largest genomics study of chordoma to date, published today (12 October) in Nature Communications, scientists show that a group of chordoma patients have mutations in genes that are the target of existing drugs, known as PI3K inhibitors.